AsoGen Therapeutics IVS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 7.9% 10.7%  
Credit score (0-100)  0 0 0 32 23  
Credit rating  N/A N/A N/A BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 -5.0 -7.0  
EBITDA  0.0 0.0 0.0 -5.0 -7.0  
EBIT  0.0 0.0 0.0 -5.0 -18.1  
Pre-tax profit (PTP)  0.0 0.0 0.0 -16.6 -39.3  
Net earnings  0.0 0.0 0.0 -16.6 -39.3  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -16.6 -39.3  

 
See the entire income statement

Balance sheet (kDKK) 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 -16.4 -55.7  
Interest-bearing liabilities  0.0 0.0 0.0 261 272  
Balance sheet total (assets)  0.0 0.0 0.0 265 238  

Net Debt  0.0 0.0 0.0 120 250  
 
See the entire balance sheet

Volume 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 -5.0 -7.0  
Gross profit growth  0.0% 0.0% 0.0% 0.0% -40.1%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 265 238  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% -9.9%  
Added value  0.0 0.0 0.0 -5.0 -7.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 99 100  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 100.0% 258.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -1.8% -6.3%  
ROI %  0.0% 0.0% 0.0% -1.9% -6.8%  
ROE %  0.0% 0.0% 0.0% -6.3% -15.6%  

Solidity 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
Equity ratio %  0.0% 0.0% 0.0% -5.9% -19.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -2,396.6% -3,572.5%  
Gearing %  0.0% 0.0% 0.0% -1,587.0% -487.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 8.9% 8.0%  

Liquidity 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
Quick Ratio  0.0 0.0 0.0 8.3 1.3  
Current Ratio  0.0 0.0 0.0 8.3 1.3  
Cash and cash equivalent  0.0 0.0 0.0 141.1 21.3  

Capital use efficiency 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 1,460.0 1,172.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 146.0 6.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
N/A
2017
N/A
2018
N/A
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0